Skip to main content
SpringerLink
Log in

Managing Scalp Psoriasis: An Evidence-Based Review

  • Evidence-Based Review
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Background

Scalp psoriasis is commonly the initial presentation of psoriasis, and almost 80 % of patients with psoriasis will eventually experience it.

Objective

Although several systematic reviews and guidelines exist, an up-to-date evidence-based review including more recent progress on the use of biologics and new oral small molecules was timely.

Methods

Of the 475 studies initially retrieved from PubMed and the 845 from Embase (up to May 2016), this review includes 27 clinical trials, four papers reporting pooled analyses of other clinical trials, ten open-label trials, one case series, and two case reports after excluding non-English literature.

Results

To our knowledge, few randomized controlled trials (RCTs) are conducted specifically in scalp psoriasis. Topical corticosteroids provide good effects and are usually recommended as first-line treatment. Calcipotriol–betamethasone dipropionate is well tolerated and more effective than either of its individual components. Localized phototherapy is better than generalized phototherapy on hair-bearing areas. Methotrexate, cyclosporine, fumaric acid esters, and acitretin are well-recognized agents in the treatment of psoriasis, but we found no published RCTs evaluating these agents specifically in scalp psoriasis. Biologics and new small-molecule agents show excellent effects on scalp psoriasis, but the high cost of these treatments mean they may be limited to use in extensive scalp psoriasis.

Conclusions

More controlled studies are needed for an evidence-based approach to scalp psoriasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Chan CS, Van Voorhees AS, Lebwohl MG, Korman NJ, Young M, Bebo BF Jr, et al. Treatment of severe scalp psoriasis: from the medical board of the national psoriasis foundation. J Am Acad Dermatol. 2009;60(6):962–71.

    Article  PubMed  Google Scholar 

  2. Mason AR, Mason JM, Cork MJ, Hancock H, Dooley G. Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. Br J Dermatol. 2013;169(3):519–27.

    Article  CAS  PubMed  Google Scholar 

  3. Osier E, Gomez B, Eichenfield LF. Adolescent scalp psoriasis: update on topical combination therapy. J Clin Aesthet Dermatol. 2015;8(7):43–7.

    PubMed  PubMed Central  Google Scholar 

  4. Papp K, Berth-Jones J, Kragballe K, Wozel G, de la Brassinne M. Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007;21(9):1151–60.

    Article  CAS  PubMed  Google Scholar 

  5. Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, et al. Topical treatments for scalp psoriasis. Cochrane Database Syst Rev. 2016;2:CD009687.

    PubMed  Google Scholar 

  6. Ortonne J, Chimenti S, Luger T, Puig L, Reid F, Trueb RM. Scalp psoriasis: European consensus on grading and treatment algorithm. J Eur Acad Dermatol Venereol. 2009;23(12):1435–44.

    Article  PubMed  Google Scholar 

  7. Feldman SR, Housman TS. Patients’ vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4(4):221–4.

    Article  PubMed  Google Scholar 

  8. Stein L. Clinical studies of a new vehicle formulation for topical corticosteroids in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(Suppl. 1):S39–49.

    Article  PubMed  Google Scholar 

  9. Abraham A, Roga G. Topical steroid-damaged skin. Indian J Dermatol. 2014;59(5):456–9.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Turpeinen M. Adrenocortical response to adrenocorticotropic hormone in relation to duration of topical therapy and percutaneous absorption of hydrocortisone in children with dermatitis. Eur J Pediatr. 1989;148(8):729–31.

    Article  CAS  PubMed  Google Scholar 

  11. Lassus A. Local treatment of psoriasis of the scalp with clobetasol propionate and betamethasone-17,21-dipropionate: a double-blind comparison. Curr Med Res Opin. 1976;4(5):365–7.

    Article  CAS  PubMed  Google Scholar 

  12. Jarratt M, Breneman D, Gottlieb AB, Poulin Y, Liu Y, Foley V. Clobetasol propionate shampoo 0.05 %: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol. 2004;3(4):367–73.

    PubMed  Google Scholar 

  13. Andres P, Poncet M, Farzaneh S, Soto P. Short-term safety assessment of clobetasol propionate 0.05 % shampoo: hypothalamic-pituitary adrenal axis suppression, atrophogenicity, and ocular safety in subjects with scalp psoriasis. J Drugs Dermatol. 2006;5(4):328–32.

    PubMed  Google Scholar 

  14. Reygagne P, Mrowietz U, Decroix J, de Waard-van der Spek FB, Acebes LO, Figueiredo A, et al. Clobetasol propionate shampoo 0.05 % and calcipotriol solution 0.005 %: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatol Treat. 2005;16(1):31–6.

    Article  CAS  Google Scholar 

  15. Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05 % shampoo and tar blend 1 % shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatol Treat. 2006;17(2):90–5.

    Article  CAS  Google Scholar 

  16. Willis I, Cornell RC, Penneys NS, Zaias N. Multicenter study comparing 0.05 % gel formulations of desoximetasone and fluocinonide in patients with scalp psoriasis. Clin Ther. 1986;8(3):275–82.

    CAS  PubMed  Google Scholar 

  17. Andreassi L, Giannetti A. Milani M; scale investigators group. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: an open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol. 2003;148(1):134–8.

    Article  CAS  PubMed  Google Scholar 

  18. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12 %: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38(8):628–32.

    Article  CAS  PubMed  Google Scholar 

  19. Klaber MR, Hutchinson PE, Pedvis-Leftick A, Kragballe K, Reunala TL, Van de Kerkhof PC, et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol. 1994;131(5):678–83.

    Article  CAS  PubMed  Google Scholar 

  20. Pauporte M, Maibach H, Lowe N, Pugliese M, Friedman DJ, Mendelsohn H, et al. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatol Treat. 2004;15(6):360–4.

    Article  CAS  Google Scholar 

  21. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative effects of calcipotriol (MC 903) solution and placebo (vehicle of MC 903) in the treatment of psoriasis of the scalp. Br J Dermatol. 1994;130(4):483–7.

    Article  CAS  PubMed  Google Scholar 

  22. Okubo Y, Natsume S, Usui K, Muro M, Tsuboi R. Combination therapy using maxacalcitol and corticosteroid lotions preliminary to monotherapy with maxacalcitol lotion for scalp psoriasis. J Dermatol Treat. 2014;25(1):34–7.

    Article  CAS  Google Scholar 

  23. Tyring S, Mendoza N, Appell M, Bibby A, Foster R, Hamilton T, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalppsoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol. 2010;49(11):1328–33.

    Article  CAS  PubMed  Google Scholar 

  24. Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology. 2008;217(2):107–13.

    Article  CAS  PubMed  Google Scholar 

  25. Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol. 2009;161(1):159–66.

    Article  CAS  PubMed  Google Scholar 

  26. Ma L, Yang Q, Yang H, Wang G, Zheng M, Hao F, et al. Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population. Int J Dermatol. 2016;55(1):106–13.

    Article  CAS  PubMed  Google Scholar 

  27. Luger TA, Cambazard F, Larsen FG, Bourcier M, Gupta G, Clonier F, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology. 2008;217(4):321–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Jemec GB, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno P, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008;59(3):455–63.

    Article  PubMed  Google Scholar 

  29. van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: arandomized, double-blind, controlled trial. Br J Dermatol. 2009;160(1):170–6.

    Article  PubMed  Google Scholar 

  30. Gooderham M, Debarre JM, Keddy-Grant J, Xu Z, Kurvits M, Goodfield M. Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age. Br J Dermatol. 2015;171(6):1470–7.

    Article  Google Scholar 

  31. Eichenfield LF, Ganslandt C, Kurvits M, Schlessinger J. Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years. Pediatr Dermatol. 2015;32(1):28–35.

    Article  PubMed  Google Scholar 

  32. Oostveen AM, de Jong EM, Donders AR, van de Kerkhof PC, Seyger MM. Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children’s quality of life in daily practice. J Eur Acad Dermatol Venereol. 2015;29(6):1193–7.

    Article  CAS  PubMed  Google Scholar 

  33. Gual A, Pau-Charles I, Molin S. Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice. J Dermatol Treat. 2016;27(3):228–34.

    Article  CAS  Google Scholar 

  34. Kragballe K, van de Kerkhof P. Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp. J Eur Acad Dermatol Venereol. 2014;28(Suppl. 2):10–21.

    Article  CAS  PubMed  Google Scholar 

  35. Saraceno R, Camplone G, D’Agostino M, De Simone C, Di Cesare A, Filosa G, et al. Efficacy and maintenance strategies of two-compound formulation calcipotriol and betamethasonedipropionate gel (xamiol® gel) in the treatment of scalp psoriasis: results from a study in 885 patients. J Dermatol Treat. 2014;25(1):30–3.

    Article  CAS  Google Scholar 

  36. Arnold WP. Tar. Clin Dermatol. 1997;15(5):739–44.

    Article  CAS  PubMed  Google Scholar 

  37. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3: guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–59.

    Article  PubMed  Google Scholar 

  38. Cunliffe WJ, Dodman B. A comparison of tar liquid and cetrimide shampoo in the management of psoriasis of the scalp. Br J Clin Pract. 1974;28(9):314–5.

    CAS  PubMed  Google Scholar 

  39. Kircik L. Salicylic Acid 6 % in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis. J Drugs Dermatol. 2011;10(3):270–3.

    CAS  PubMed  Google Scholar 

  40. Shokeen D, O’Neill JL, Taheri A, Feldman SR. Are topical keratolytic agents needed in the treatment of scalp psoriasis? Dermatol Online J. 2014;20(3). http://escholarship.org/uc/item/7g56436q.

  41. Hovding G. Treatment of psoriasis of the scalp with betamethasone 17, 21-dipropionate plus salicylic acid lotion (‘diprosalic’). Pharmatherapeutica. 1981;3(1):61–6.

    CAS  PubMed  Google Scholar 

  42. Roberts DL, Marshall R, Marks R. Detection of the action of salicylic acid on the normal stratum corneum. Br J Dermatol. 1980;103(2):191–6.

    Article  CAS  PubMed  Google Scholar 

  43. Solomon AE, Lowe NJ. Percutaneous absorption in experimental epidermal disease. Br J Dermatol. 1979;100(6):717–22.

    Article  CAS  PubMed  Google Scholar 

  44. Hillstrom L. Comparison of topical treatment with desoxymethasone solution 0.25 % with salicylic acid 1 % and betamethasone valerate solution 0.1 % in patients with psoriasis of the scalp. J Int Med Res. 1984;12(3):170–3.

    Article  CAS  PubMed  Google Scholar 

  45. Hillstrom L, Pettersson L, Svensson L. Comparison of betamethasone dipropionate lotion with salicylic acid (diprosalic) and clobetasol propionate lotion (dermovate) in the treatment of psoriasis of the scalp. J Int Med Res. 1982;10(6):419–22.

    CAS  PubMed  Google Scholar 

  46. Elie R, Durocher LP, Kavalec EC. Effect of salicylic acid on the activity of betamethasone-17,21-dipropionate in the treatment of erythematous squamous dermatoses. J Int Med Res. 1983;11(2):108–12.

    Article  CAS  PubMed  Google Scholar 

  47. Fartasch M, Teal J, Menon GK. Mode of action of glycolic acid on human stratum corneum: ultrastructural and functional evaluation of the epidermal barrier. Arch Dermatol Res. 1997;289(7):404–9.

    Article  CAS  PubMed  Google Scholar 

  48. Kostarelos K, Teknetzis A, Lefaki I, Ioannides D, Minas A. Double-blind clinical study reveals synergistic action between alpha-hydroxy acid and betamethasone lotions towards topical treatment of scalp psoriasis. J Eur Acad Dermatol Venereol. 2000;14(1):5–9.

    Article  CAS  PubMed  Google Scholar 

  49. Kemény L, Ruzicka T, Braun-Falco O. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol. 1990;3(1):1–20.

    Article  PubMed  Google Scholar 

  50. Wulff-Woesten A, Ohlendorf D, Henz BM, Haas N. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol. 2004;17(2):91–7.

    Article  CAS  PubMed  Google Scholar 

  51. Gollnick HP, Finzi AF, Marks R, Barker JN, Jansen C, Revuz J, et al. Optimising the use of tazarotene in clinical practice: consensus statement from the European advisory panel for tazarotene (zorac TM). Dermatology. 1999;199(1):40–6.

    Article  CAS  PubMed  Google Scholar 

  52. Taneja A, Racette A, Gourgouliatos Z, Taylor CR. Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study. Int J Dermatol. 2004;43(6):462–7.

    Article  PubMed  Google Scholar 

  53. Gattu S, Rashid RM, Wu JJ. 308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis. J Eur Acad Dermatol Venereol. 2009;23(1):36–41.

    Article  CAS  PubMed  Google Scholar 

  54. Morison WL, Atkinson DF, Werthman L. Effective treatment of scalp psoriasis using the excimer (308 nm) laser. Photodermatol Photoimmunol Photomed. 2006;22(4):181–3.

    Article  PubMed  Google Scholar 

  55. Lindelöf B. Grenz ray therapy in dermatology. An experimental, clinical and epidemiological study. Acta Derm Venereol Suppl (Stockh). 1987;132:1–67.

    PubMed  Google Scholar 

  56. Lindelöf B, Johannesson A. Psoriasis of the scalp treated with grenz rays or topical corticosteroid combined with grenz rays. a comparative randomized trial. Br J Dermatol. 1988;119(2):241–4.

    Article  PubMed  Google Scholar 

  57. Farr PM, Krause LB, Marks JM, Shuster S. Response of scalp psoriasis to oral ketoconazole. Lancet. 1985;2(8461):921–2.

    Article  CAS  PubMed  Google Scholar 

  58. Faergemann J, Diehl U, Bergfelt L, Brodd A, Edmar B, Hersle K, et al. Scalp psoriasis: synergy between the Malassezia yeasts and skin irritation due to calcipotriol. Acta Derm Venereol. 2003;83(6):438–41.

    Article  CAS  PubMed  Google Scholar 

  59. Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol. 2012;67(1):86–92.

    Article  PubMed  Google Scholar 

  60. Tyring S, Bagel J, Lynde C, Klekotka P, Thompson EH, Gandra SR, et al. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from arandomized, double-blind, placebo-controlled study of etanercept. J Eur Acad Dermatol Venereol. 2013;27(1):125–8.

    Article  CAS  PubMed  Google Scholar 

  61. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol. 2003;49(Suppl. 2):S112–7.

    Article  PubMed  Google Scholar 

  62. Torii H, Sato N, Yoshinari T, Nakagawa H, Japanese infliximab study investigators. Dramatic impact of a psoriasis area and severity index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. J Dermatol. 2012;39(3):253–9.

    Article  CAS  PubMed  Google Scholar 

  63. Torii H, Nakagawa H, Japanese infliximab study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. a randomized, double-blind, placebo controlled multicenter trial. J Dermatol Sci. 2010;59(1):40–9.

    Article  CAS  PubMed  Google Scholar 

  64. Torii H, Nakagawa H, Japanese infliximab study investigators. Long term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. J Dermatol. 2011;38(4):321–34.

    Article  CAS  PubMed  Google Scholar 

  65. Menter A, Reich K, Li S, Guzzo C. Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: results from controlled clinical trials. J Am Acad Dermatol. 2008;58(Suppl. 2):AB120.

    Google Scholar 

  66. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–74.

    Article  CAS  PubMed  Google Scholar 

  67. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1–e15.

  68. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–42.

    Article  PubMed  Google Scholar 

  69. Thaçi D, Unnebrink K, Sundaram M, Sood S, Yamaguchi Y. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects onscalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015;29(2):353–60.

    Article  PubMed  Google Scholar 

  70. Wang TS, Tsai TF. Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept. Dermatol Sinica. 2013;31(1):11–8.

    Article  Google Scholar 

  71. Papadavid E, Ferra D, Koumaki D, Dalamaga M, Stamou C, Theodoropoulos K, et al. Ustekinumab induces fast response and maintenance of very severe refractory scalp psoriasis: results in two Greek patients from the psoriasis hospital-based clinic. Dermatology. 2014;228(2):107–11.

    Article  CAS  PubMed  Google Scholar 

  72. Di Cesare A, Fargnoli MC, Peris K. Rapid response of scalp psoriasis to ustekinumab. Eur J Dermatol. 2011;21(6):993–4.

    PubMed  Google Scholar 

  73. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.

    Article  PubMed  Google Scholar 

  74. Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–93.

    Article  CAS  PubMed  Google Scholar 

  75. Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–90.

    Article  CAS  PubMed  Google Scholar 

  76. Kircik L, Fowler J, Weiss J, Meng X, Guana A, Nyirady J. Efficacy of secukinumab in the treatment of moderate-to-severe plaque psoriasis on the head and neck: pooled analysis of phase 3 studies. Poster presented at: American academy of dermatology 73rd annual meeting, San Francisco, CA, March 20–24, 2015.

  77. Langley RG, Rich P, Menter A, Krueger G, Goldblum O, Dutronc Y, et al. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015;29(9):1763–70.

    Article  CAS  PubMed  Google Scholar 

  78. Reich K, Lebwohl M, Romiti R. Impact of ixekizumab treatment on scalp psoriasis: results from the UNCOVER-2 trial. Poster presented at: American academy of dermatology 74th annual meeting, Washington, DC, March 4, 2016.

  79. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–90.

    Article  CAS  PubMed  Google Scholar 

  80. Rich P, Gooderham M, Bachelez H, Goncalves J, Day RM, Chen R, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134–42.

    Article  CAS  PubMed  Google Scholar 

  81. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (ESTEEM 1). J Am Acad Dermatol. 2015;73(1):37–49.

    Article  CAS  PubMed  Google Scholar 

  82. Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–99.

    Article  CAS  PubMed  Google Scholar 

  83. Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, et al. Tofacitinib, an oral janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949–61.

    Article  CAS  PubMed  Google Scholar 

  84. Bissonnette R, Iversen L, Sofen H, Griffiths CE, Foley P, Romiti R, et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis:a randomized controlled trial. Br J Dermatol. 2015;172:1395–406.

    Article  CAS  PubMed  Google Scholar 

  85. Chen HH, Tseng MP, Tsai TF. An epidemiologic study of Taiwanese psoriatic patients in a single clinic. Dermatol Sinica. 2003;21(3):216–24.

    CAS  Google Scholar 

  86. Wang TS, Tsai TF. Intralesional therapy for psoriasis. J Dermatol Treat. 2013;24(5):340–7.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan

    Ting-Shun Wang

  2. Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, #7, Chung-Shan South Road, Taipei, Taiwan

    Ting-Shun Wang & Tsen-Fang Tsai

Authors
  1. Ting-Shun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsen-Fang Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tsen-Fang Tsai.

Ethics declarations

Funding

No sources of funding were used to conduct this study or prepare this manscript.

Conflict of interest

Dr. Tsai has conducted clinical trials or received honoraria for serving as a consultant for Pfizer, Novartis, Celgene, Eli-Lilly, and Janssen-Cilag Pharmaceuticals and has received speaking fees from Abbvie. Dr. Wang has received speaking fees from Abbvie and Janssen-Cilag Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, TS., Tsai, TF. Managing Scalp Psoriasis: An Evidence-Based Review. Am J Clin Dermatol 18, 17–43 (2017). https://doi.org/10.1007/s40257-016-0222-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-016-0222-4

Keywords

Search

Navigation